Articles by Saeed Sadeghi, MD
Our expert roundtable reacts to data presented at ASCO 2025 on real-world use of the agent in this setting.
Experts discuss what data do clinicians need in order to optimize their first-line use of this agent for low-risk MDS.
Our expert panel reacts to the updated efficacy and safety data for luspatercept presented at ASCO 2025.
Panelists discuss how these biomarkers factor into their therapy choices and the impact of new data from ASCO 2025.
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.